{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:41:17Z","timestamp":1791438077654,"version":"4.3.3"},"reference-count":21,"publisher":"Informa UK Limited","issue":"18","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA, Darmstadt, Germany","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.2217\/fon-2020-1250","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T10:14:00Z","timestamp":1615544040000},"page":"2339-2350","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["Real-World Clinical Outcomes with First-Line Avelumab in Locally Advanced\/metastatic Merkel Cell Carcinoma in the USA: SPEAR-Merkel"],"prefix":"10.1080","volume":"17","author":[{"given":"Charles Lance","family":"Cowey","sequence":"first","affiliation":[{"name":"Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX75246, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank X","family":"Liu","sequence":"additional","affiliation":[{"name":"EMD Serono, Inc., Rockland, MA02370, USA; an affiliate of Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Kim","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY10017, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marley","family":"Boyd","sequence":"additional","affiliation":[{"name":"McKesson Life Sciences, The Woodlands, TX77380, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Fulcher","sequence":"additional","affiliation":[{"name":"McKesson Life Sciences, The Woodlands, TX77380, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Krulewicz","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Kasturi","sequence":"additional","affiliation":[{"name":"EMD Serono, Inc., Rockland, MA02370, USA; an affiliate of Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Bhanegaonkar","sequence":"additional","affiliation":[{"name":"EMD Serono, Inc., Rockland, MA02370, USA; an affiliate of Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.11.020"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-4-7"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S72202"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.329"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2779-3"},{"key":"e_1_3_6_8_1","unstructured":"American Cancer Society . Survival rates for Merkel cell carcinoma. (2020).https:\/\/www.cancer.org\/cancer\/merkel-cell-skin-cancer\/detection-diagnosis-staging\/survival-rates.html."},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.10.022"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.815"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0187"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0072"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19218"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000313"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0310-x"},{"key":"e_1_3_6_16_1","volume-title":"SITC 2019 Congress, 6\u201310 November 2019","author":"D'Angelo SP","year":"2019","unstructured":"D'Angelo SP , LebbeC, MortierLet al. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: primary analysis after \u226515 months of follow-up from JAVELIN Merkel 200, a registrational Phase 2 trial. SITC 2019 Congress, 6\u201310 November 2019National Harbor, MD, USA (2019)."},{"key":"e_1_3_6_17_1","unstructured":"National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Merkel cell carcinoma. V1(2020). (2020). https:\/\/merkelcell.org\/wp-content\/uploads\/2017\/10\/MCC_v.2.2019-2.pdf"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0055"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)02108-X"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2009.01370.x"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.09.036"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.13039"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001076"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2020-1250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:17Z","timestamp":1719124997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-1250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":21,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.2217\/fon-2020-1250"],"URL":"https:\/\/doi.org\/10.2217\/fon-2020-1250","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}